Published March 1, 2009 | Version v1
Journal article

Study to Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by Detailing Patterns of Recurrence After Definitive Chemoradiotherapy

  • 1. Department of Clinical Oncology, Velindre Oncology Centre, Cardiff (United Kingdom)
  • 2. Department of Clinical Oncology, Bristol Oncology Centre, Bristol (United Kingdom)
  • 3. Chase Farm Hospital, Enfield, Middlesex (United Kingdom)
  • 4. Department of Radiology, University Hospital of Wales, Cardiff (United Kingdom)

Description

Purpose: To ascertain the adequacy of radiotherapy (RT) margins by studying the relapse patterns after definitive chemoradiotherapy for carcinoma of the esophagus. Methods and Materials: We performed a retrospective study assessing the first site of disease relapse after definitive chemoradiotherapy that included four 3-weekly cycles of cisplatin and continuous infusion 5-fluorouracil, with conformal RT (50 Gy in 25 fractions) concurrent with Cycles 3 and 4. The RT planning target volume was the endoscopic ultrasonography/computed tomography-defined gross tumor volume with 1.5-cm lateral and 3-cm superoinferior margins. Results: A total of 145 patients were included. Their average age was 65.4 years, 45% had adenocarcinoma, 61% had lower third esophageal tumors, and 75% had Stage III-IVA disease. After RT, of 142 patients, 85 (60%) had evidence of relapse at a median follow-up of 18 months. The relapse was local (within the RT field) in 55; distant (metastatic) in 13, and a combination of local and distant in 14. The local relapse rates were not influenced by tumor stage, lymph node status, or disease length. Three patients developed a relapse in regions adjacent to the RT fields; however, it is unlikely that larger field margins would have been clinically acceptable or effective in these cases. The median overall survival was 15 months. Conclusion: The gross tumor volume-planning target volume margins in this study appeared adequate. Future efforts to improve outcomes using definitive chemoradiotherapy should be directed toward reducing the high rates of in-field and distant relapses

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2008.04.062

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2008.04.062;
PII
S0360-3016(08)00822-5;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
73
Journal Issue
3
Journal Page Range
p. 818-823
ISSN
0360-3016
CODEN
IOBPD3

Optional Information

Copyright
Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.